Head to head comparison teriparatide products daily versus weekly for osteoporosis patients.
Not Applicable
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000024503
- Lead Sponsor
- Department of rheumatology, Takarazuka city hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
The patient who has poor control of the underlying disease in the glucocorticoid osteoporosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The new bone fracture incidence until 18 months after treatment intervention.
- Secondary Outcome Measures
Name Time Method Change of the serologic marker about bone metabolism and the bone density 1, 6, 12, 18 and 30 months later. The new bone fracture incidence until 30 months after treatment intervention. serologic marker: TRACP-5b, total P1NP, 1,25(OH)2VitD3, Ca, IP